Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4884 in Advanced/Metastatic Solid Tumors
NCT07600749Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of MK-4884 in solid tumor (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 39 months and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
MK-4884
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07600749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600749.